Search results
Feb 17, 2022 · Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2021, and provided its financial guidance for full-year and first-quarter 2022.
Feb 9, 2023 · On an adjusted basis, 2022 net income attributable to Baxter totaled $1.8 billion, or $3.50 per diluted share, a decline of 3% compared to the prior-year period. For the full year, Baxter generated $1.2 billion in operating cash flow from continuing operations and $532 million in free cash flow (operating cash flow from continuing operations ...
Apr 28, 2022 · First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1. First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93. Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant currency ...
Feb 9, 2023 · Baxter's worldwide sales in the fourth quarter totaled $3.9 billion, an increase of 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis. Operational sales in the fourth quarter exclude the impacts of foreign exchange and the December 2021 acquisition of Hillrom.
Gross Margin. The company’s results in 2022 and 2021 included intangible asset amortization expense of $753 million ($580 million, or $1.14 per diluted share, on an after-tax basis) and $298 million ($234 million, or $0.46 per diluted share, on an after-tax basis), respectively.
Gross Margin. The company’s results in 2022 and 2021 included intangible asset amortization expense of $578 million ($441 million, or $0.87 per diluted share, on an after-tax basis) and $199 million ($158 million, or $0.31 per diluted share, on an after-tax basis), respectively.
People also ask
What will Baxter's earnings look like in 2022?
How much did Baxter sell in 2021?
What was Baxter's net income in the fourth quarter?
How much cash does Baxter generate a year?
How did Baxter perform in 2022?
What is Baxter's financial outlook for 2023?
Feb 21, 2024 · Baxter is an established market leader in big pharma and medical supplies, with expected EPS growth and declining debt. Learn why BAX stock is a Buy.
